Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABP NASDAQ:BFRG NASDAQ:CLRB NASDAQ:ENVB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABPAbpro$0.19+0.9%$0.22$0.15▼$13.00$15.20M0.024.56 million shs866,529 shsBFRGBullfrog AI$1.47$1.34$1.09▼$4.84$15.07M0.53448,862 shs69,611 shsCLRBCellectar Biosciences$4.50-5.3%$5.02$4.11▼$66.00$15.16M0.59113,413 shs140,453 shsENVBEnveric Biosciences$0.76-3.7%$0.90$0.56▼$8.33$4.90M0.6799,373 shs277,991 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABPAbpro-0.21%+3.04%-1.76%-7.01%+18,959,900.00%BFRGBullfrog AI0.00%+11.36%+13.08%-2.65%-45.15%CLRBCellectar Biosciences-5.26%-3.02%-11.07%-9.82%-92.79%ENVBEnveric Biosciences-3.68%+21.46%+17.34%-42.49%-89.51%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABPAbpro$0.19+0.9%$0.22$0.15▼$13.00$15.20M0.024.56 million shs866,529 shsBFRGBullfrog AI$1.47$1.34$1.09▼$4.84$15.07M0.53448,862 shs69,611 shsCLRBCellectar Biosciences$4.50-5.3%$5.02$4.11▼$66.00$15.16M0.59113,413 shs140,453 shsENVBEnveric Biosciences$0.76-3.7%$0.90$0.56▼$8.33$4.90M0.6799,373 shs277,991 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABPAbpro-0.21%+3.04%-1.76%-7.01%+18,959,900.00%BFRGBullfrog AI0.00%+11.36%+13.08%-2.65%-45.15%CLRBCellectar Biosciences-5.26%-3.02%-11.07%-9.82%-92.79%ENVBEnveric Biosciences-3.68%+21.46%+17.34%-42.49%-89.51%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABPAbpro 2.00Hold$4.002,009.70% UpsideBFRGBullfrog AI 1.00SellN/AN/ACLRBCellectar Biosciences 2.20Hold$375.008,233.33% UpsideENVBEnveric Biosciences 2.00Hold$10.001,217.35% UpsideCurrent Analyst Ratings BreakdownLatest ENVB, CLRB, BFRG, and ABP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025ABPAbproWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025BFRGBullfrog AIWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025CLRBCellectar BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025ENVBEnveric BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025ABPAbproWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025BFRGBullfrog AIWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025CLRBCellectar BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025ENVBEnveric BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)8/14/2025CLRBCellectar BiosciencesRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 10/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABPAbpro$183K83.06N/AN/A($0.29) per share-0.65BFRGBullfrog AI$60K251.13N/AN/A$0.57 per share2.58CLRBCellectar BiosciencesN/AN/AN/AN/A$8.98 per shareN/AENVBEnveric BiosciencesN/AN/AN/AN/A$2.35 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABPAbpro-$7.23MN/A0.00∞N/AN/AN/A-241.16%11/12/2025 (Estimated)BFRGBullfrog AI-$6.99M-$0.76N/A∞N/AN/A-195.35%-162.37%11/14/2025 (Estimated)CLRBCellectar Biosciences-$44.58M-$19.91N/AN/AN/AN/A-486.67%-150.57%11/17/2025 (Estimated)ENVBEnveric Biosciences-$9.57M-$38.38N/AN/AN/AN/A-341.48%-240.71%11/13/2025 (Estimated)Latest ENVB, CLRB, BFRG, and ABP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CLRBCellectar Biosciences-$3.60-$3.39+$0.21-$3.39N/AN/A8/14/2025Q2 2025ENVBEnveric Biosciences-$5.25-$0.97+$4.28-$0.97N/AN/A8/13/2025Q2 2025ABPAbproN/A-$0.04N/A-$0.05N/AN/A8/13/2025Q2 2025BFRGBullfrog AIN/A-$0.15N/A-$0.15N/A$0.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABPAbproN/AN/AN/AN/AN/ABFRGBullfrog AIN/AN/AN/AN/AN/ACLRBCellectar BiosciencesN/AN/AN/AN/AN/AENVBEnveric BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABPAbproN/A0.150.15BFRGBullfrog AIN/A3.973.97CLRBCellectar BiosciencesN/A2.152.15ENVBEnveric BiosciencesN/A2.422.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABPAbpro23.30%BFRGBullfrog AI0.96%CLRBCellectar Biosciences16.41%ENVBEnveric Biosciences13.82%Insider OwnershipCompanyInsider OwnershipABPAbpro13.70%BFRGBullfrog AI25.16%CLRBCellectar Biosciences5.04%ENVBEnveric Biosciences1.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABPAbpro1580.17 million69.18 millionN/ABFRGBullfrog AI410.25 million7.67 millionNot OptionableCLRBCellectar Biosciences103.19 million3.03 millionOptionableENVBEnveric Biosciences206.22 million6.15 millionNot OptionableENVB, CLRB, BFRG, and ABP HeadlinesRecent News About These CompaniesAbbVie ends in green six straight sessions of declinesOctober 16 at 5:43 PM | msn.comEnveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent IssuanceOctober 16 at 8:30 AM | businesswire.comEnveric Biosciences to explore digital asset treasury strategy opportunitiesOctober 14, 2025 | msn.comEnveric Biosciences to Explore Digital Asset Treasury OpportunitiesOctober 14, 2025 | pharmiweb.comPEnveric Biosciences' (ENVB) Sell (E+) Rating Reaffirmed at Weiss RatingsOctober 9, 2025 | americanbankingnews.comPsychedelic: Enveric announces EB-003 manufacturing milestonesOctober 2, 2025 | msn.comEnveric Biosciences completes key manufacturing milestones for EB-003October 2, 2025 | msn.comEnveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical TrialsOctober 2, 2025 | businesswire.comEnveric Biosciences files to sell 5.02M shares of common stock for holdersSeptember 29, 2025 | msn.comEnveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross ProceedsSeptember 18, 2025 | businesswire.comEnveric Biosciences publishes two peer-reviewed research papersSeptember 17, 2025 | msn.comEnveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross ProceedsSeptember 17, 2025 | businesswire.comEnveric Biosciences receives FDA response, streamlines path for EB-003September 16, 2025 | msn.comEnveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND SubmissionSeptember 16, 2025 | businesswire.comEnveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 5, 2025 | finance.yahoo.comEnveric Biosciences Releases New Investor PresentationAugust 29, 2025 | tipranks.comEnveric Tanks on Successful TestsAugust 28, 2025 | baystreet.caEnveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric IndicationsAugust 28, 2025 | bakersfield.comBEnveric Biosciences Announces Preclinical Results Confirming Potential ...August 17, 2025 | businesswire.comEnveric Biosciences Reports Second Quarter 2025 Financial and Corporate ResultsAugust 15, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeENVB, CLRB, BFRG, and ABP Company DescriptionsAbpro NASDAQ:ABP$0.19 +0.00 (+0.85%) As of 10/17/2025 04:00 PM EasternAbpro Holdings Inc. is a biotechnology company. The company's mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro Holdings Inc., formerly known as Atlantic Coastal Acquisition Corp. II, is based in WOBURN, Mass.Bullfrog AI NASDAQ:BFRG$1.47 0.00 (0.00%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$1.47 0.00 (-0.27%) As of 10/17/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.Cellectar Biosciences NASDAQ:CLRB$4.50 -0.25 (-5.26%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$4.56 +0.06 (+1.33%) As of 10/17/2025 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.Enveric Biosciences NASDAQ:ENVB$0.76 -0.03 (-3.68%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$0.75 -0.01 (-1.33%) As of 10/17/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave Archer Buys Rival's Patent Treasure Trove in Strategic Move Prologis Stock Surges: Why the Rally May Continue Intel's Turnaround Hits Hyperspeed With A New 52-Week High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
